| 3.42 -0.01 (-0.29%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.93 |
1-year : | 5.87 |
| Resists | First : | 4.22 |
Second : | 5.03 |
| Pivot price | 3.49 |
|||
| Supports | First : | 2.92 | Second : | 2.42 |
| MAs | MA(5) : | 3.47 |
MA(20) : | 3.48 |
| MA(100) : | 6.38 |
MA(250) : | 6.32 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 24.3 |
D(3) : | 25.6 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 11.19 | Low : | 2.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KALA ] has closed above bottom band by 43.9%. Bollinger Bands are 52.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.69 - 3.71 | 3.71 - 3.73 |
| Low: | 3.29 - 3.31 | 3.31 - 3.33 |
| Close: | 3.38 - 3.42 | 3.42 - 3.46 |
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Mon, 31 Mar 2025
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Wed, 12 Feb 2025
Kala Bio announces CEO departure, appoints interim leader - Investing.com
Wed, 12 Feb 2025
Kala Bio appoints new interim CEO amid leadership shuffle - Investing.com
Fri, 03 Jan 2025
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc - GuruFocus
Mon, 30 Dec 2024
Kala Bio raises $10.75 million in private placement - Investing.com
Thu, 27 Jun 2024
KALA BIO Announces $12,500,000 Private Placement - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 56.7 (%) |
| Shares Short | 405 (K) |
| Shares Short P.Month | 266 (K) |
| EPS | -10.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.4 % |
| Return on Equity (ttm) | -388.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.34 |
| PEG Ratio | 0 |
| Price to Book value | 1.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|